BCMA Knockout RPMI-8226 Cell Line

Description

BCMA-KO RPMI-8226 cell line is a genetically engineered multiple myeloma model generated via CRISPR/Cas9-mediated knockout to eliminate BCMA/CD269 expression. This BCMA knockout cell line maintains native plasma cell characteristics and enables functional studies of B-cell maturation antigen signaling in plasma cell malignancies, providing a controlled platform for evaluating BCMA-targeted immunotherapies (e.g., CAR-T cells, bispecific antibodies) and investigating compensatory survival pathways in BCMA-null contexts. The knockout phenotype permits mechanistic dissection of therapeutic resistance while maintaining the parental line’s relevance for hematologic malignancy research. Cryopreserved at low passage (<P20) to ensure genetic stability and consistent performance. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast and Bacteria.